These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 27920482

  • 1. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.
    Hlaing NK, Banerjee D, Mitrani R, Arker SH, Win KS, Tun NL, Thant Z, Win KM, Reddy KR.
    World J Gastroenterol; 2016 Nov 21; 22(43):9613-9622. PubMed ID: 27920482
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
    Malone DC, Tran TT, Poordad FF.
    J Manag Care Pharm; 2005 Oct 21; 11(8):687-94. PubMed ID: 16194133
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
    Fabris P, Carlotto A, Del Bianco T, Malfatti F, Tramarin A, Miotti MA, Baldo V, Floreani A, Giordani MT, Grasso A.
    Eur J Gastroenterol Hepatol; 2013 Dec 21; 25(12):1396-401. PubMed ID: 23743559
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, Todesca P, Cerami C, Sagnelli C, Rizzetto M, Cammà C, Villa E.
    World J Gastroenterol; 2014 Nov 28; 20(44):16726-33. PubMed ID: 25469044
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.
    El Naghi S, Abdel-Ghaffar TY, El-Karaksy H, Abdel-Aty EF, El-Raziky MS, Allam AA, Helmy H, El-Araby HA, Behairy BE, El-Guindi MA, El-Sebaie H, Abdel-Ghaffar AY, Ehsan NA, El-Hennawy AM, Sira MM.
    World J Gastroenterol; 2014 Apr 28; 20(16):4681-91. PubMed ID: 24782620
    [Abstract] [Full Text] [Related]

  • 10. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR, Zhang X, Yang ZG, Li P, Gao L, Chen XH, Wang J, Xiong X, Wang SM, Geng JB, Hao KY, Xie F, Wang M, Zheng WK.
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar 20; 24(3):175-80. PubMed ID: 27095759
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.
    Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH.
    Clin Infect Dis; 2008 Nov 15; 47(10):1260-9. PubMed ID: 18834319
    [Abstract] [Full Text] [Related]

  • 14. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
    Laguno M, Larrousse M, Murillas J, Blanco JL, León A, Milinkovic A, Loncá M, Martinez E, Sánchez-Tapias JM, de Lazzari E, Gatell JM, Costa J, Mallolas J.
    J Acquir Immune Defic Syndr; 2007 Feb 01; 44(2):174-8. PubMed ID: 17106276
    [Abstract] [Full Text] [Related]

  • 15. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.
    Health Technol Assess; 2004 Oct 01; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D, Jones J, Baxter L, Shepherd J.
    Health Technol Assess; 2011 Apr 01; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [Abstract] [Full Text] [Related]

  • 18. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, El-Nakeeb A, Selim O, Saied A.
    Am J Gastroenterol; 2005 Nov 01; 100(11):2447-52. PubMed ID: 16279899
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.
    Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K.
    J Hepatol; 2012 May 01; 56(5):1012-1018. PubMed ID: 22266603
    [Abstract] [Full Text] [Related]

  • 20. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
    Terrier B, Lapidus N, Pol S, Serfaty L, Ratziu V, Asselah T, Thibault V, Souberbielle JC, Carrat F, Cacoub P.
    World J Gastroenterol; 2015 May 14; 21(18):5647-53. PubMed ID: 25987791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.